Combining Temozolomide with a Selective CK2 Inhibitor Results in Anti-Tumour Effects in Glioblastoma Cell Lines - PubMed
6 hours ago
- #temozolomide
- #glioblastoma
- #CK2 inhibitor
- Combining Temozolomide (TMZ) with a selective CK2 inhibitor (TF) shows anti-tumor effects in glioblastoma cell lines.
- TF reduces proliferation in A1207 glioblastoma cells with an EC50 of 13.7 µM, comparable to CX-4945 (13.9 µM).
- Combination treatment of TF and TMZ is more effective than single treatments in impairing proliferation and viability in A1207 and U87 cell lines.
- The treatment affects proliferation, metabolic activity, cytotoxicity, and induces apoptosis, with varying caspase patterns between cell lines.
- TF and TMZ combination may be a promising future treatment for glioblastoma.